Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Oncology Biomarkers Market Grown from 2024 to 2025?

In recent times, there has been a swift expansion in the scale of the oncology biomarkers market. Estimated at $15.3 billion in 2024, it is projected to swell to $17.43 billion in 2025, showcasing a compound annual growth rate (CAGR) of 13.9%. The notable growth observed in the historic phase could be ascribed to wider acceptance in developing nations, efforts towards precision medicine, advancements in diagnostic procedures, support for drug development, and a rising occurrence of cancer.

What Growth Rate Is Anticipated for the Oncology Biomarkers Market in the Coming Years?

In the coming years, the oncology biomarkers market is projected to experience swift expansion. The market is anticipated to reach $29.64 billion by 2029, with a compound annual growth rate (CAGR) of 14.2%. Factors contributing to this predicted growth during the specified period include the integration of next-generation sequencing (ngs), the growth of biomarker informatics, emphasis on predictive pharmacogenomics, quick progression of exosome-based biomarkers, and the utilization of spatial transcriptomics. Key trends expected within this period are the standardization and quality assurance, a move towards functional biomarkers, the function of biomarkers in clinical trials, wider applications in immunotherapy, and real-time observation of therapy responses.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp

Who Are the Leading Companies in the Oncology Biomarkers Market?

Major companies operating in the oncology biomarkers market include F Hoffmann-La Roche AG, Novartis AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Eli Lilly and Company, Merck KGaA, Siemens Healthcare GmbH, Becton Dickinson and Company, GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Charles River Laboratories International Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN NV, Exact Sciences Corporation, Sysmex Corporation, PerkinElmer Inc., Leica Biosystems, Myriad Genetics Inc., Guardant Health Inc., Enzo Biochem Inc., Biocartis Group NV, Bristol -Myers Squibb Company, Agendia Inc., Epigenomics AG, OncoDNA SA

What Are the Key Drivers of the Oncology Biomarkers Market?

The oncology biomarker market is predicted to expand due to the increasing prevalence of cancer. This illness begins when some cells in the body start multiplying without control, gradually affecting the whole body. Oncology biomarkers help gain a deeper insight into the specific kind of cancer by evaluating the genes, proteins, and other substances present in a patient’s body. For instance, the National Library of Medicine, a government institution based in the US, projected in January 2024, that the United States might see 2,001,140 new cancer cases and 611,720 cancer-related fatalities in 2024. On top of that, the annual incidence rates of cervical cancer among individuals between 30 and 44 years old, and colorectal cancer in those under 55 years old, have been witnessing 1% to 2% increases among the younger population. Hence, the growing cancer prevalence is expected to steer the growth in the oncology biomarker market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12493&type=smp

What Are the Key Market Segments in the Oncology Biomarkers Industry?

The oncology biomarkers market covered in this report is segmented –

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

5) By End-User: Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Cells (CTCs), Enzymatic Biomarkers

2) By Genetic Biomarkers: DNA Mutations, Gene Expression Profiles, Single Nucleotide Polymorphisms (SNPs)

3) By Other Cancer Biomarkers: Metabolomic Biomarkers, Epigenetic Biomarkers, MicroRNA Biomarkers

What Are the Latest Trends in the Oncology Biomarkers Market?

The trend of embracing groundbreaking and sophisticated technologies is prevalent in the oncology biomarker industry. To consolidate their market standing in the field of oncology biomarkers, top corporations are rolling out novel and pioneering technologies. A case in point is OncoDNA, a Belgium-based corporation specializing in precision medicine in oncology, which unveiled the OncoDEEP kit in 2022. This distinctive kit empowers laboratories to conduct thorough biomarker testing. Via the use of Next-generation sequencing (NGS) technology coupled with cloud-based software applications, OncoDEEP offers labs the means to carry out broad-panel sequencing, gain a molecular understanding of a tumor, scrutinize the raw data, and avail detailed quality control checks.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report

What Are the Key Regional Markets in the Oncology Biomarkers Industry?

North America was the largest region in the oncology biomarkers market in 2024. The regions covered in the oncology biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12493

This Report Delivers Insight On:

1. How big is the oncology biomarkers market, and how is it changing globally?

2. Who are the major companies in the oncology biomarkers market, and how are they performing?

3. What are the key opportunities and risks in the oncology biomarkers market right now?

4. Which products or customer segments are growing the most in the oncology biomarkers market?

5. What factors are helping or slowing down the growth of the oncology biomarkers market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model